Spain
ENDOLIPID THERAPEUTICS is a Spanish startup founded in 2021, dedicated to developing innovative solutions for reducing ectopic fat, including targeted therapies for NASH and Cellulite. Through mimicking the action of Sex Hormone Binding Globulin (SHBG), the company aims to effectively reduce ectopic fat, fibrosis, and inflammation.
At present, NASH represents a growing and underserved disease, and Endolipid Tx is working on EDL6D, an in vivo effective peptide that holds promise as a treatment opportunity for NASH, boasting a novel and differentiated mechanism of action. The potential impact of this novel peptide could provide a significant advancement in addressing the unmet medical needs of NASH patients.
In addition to their work on NASH, Endolipid Tx is also targeting Cellulite and Slimming, pathologies that have been largely overlooked in terms of therapeutic innovation for the past decade. The company's development of EDL81, a peptide with an innovative mode of action and demonstrated in vitro and in vivo efficacy in reducing ectopic fat in Cellulite and Slimming, promises to carve out a space for Endolipid in these underserved markets. This presents a significant potential for market disruption and growth in an area that has seen little development in recent years.
As Endolipid Therapeutics continues its endeavors to tackle these pressing medical needs, the potential for future investment and strategic partnerships with bold industry players could be on the horizon, given the promising therapeutic potential and market opportunities the company is addressing.
